Skip to Main content Skip to Navigation
Journal articles

Utility-based dose selection for phase II dose-finding studies

Abstract : Dose selection is a key feature of clinical development. Poor dose selection has been recognized as a major driver of development failure in late phase. It usually involves both efficacy and safety criteria. The objective of this paper is to develop and implement a novel fully Bayesian statistical framework to optimize the dose selection process by maximizing the expected utility in phase III. The success probability is characterized by means of a utility function with two components, one for efficacy and one for safety. Each component refers to a dose-response model. Moreover, a sequential design (with futility and efficacy rules at the interim analysis) is compared to a fixed design in order to allow one to hasten the decision to perform the late phase study. Operating characteristics of this approach are extensively assessed by simulations under a wide range of dose-response scenarios.
Document type :
Journal articles
Complete list of metadata

Cited literature [26 references]  Display  Hide  Download
Contributor : gwladys toulemonde Connect in order to contact the contributor
Submitted on : Wednesday, February 26, 2020 - 11:21:13 AM
Last modification on : Wednesday, May 18, 2022 - 3:45:46 AM
Long-term archiving on: : Wednesday, May 27, 2020 - 3:22:48 PM


Files produced by the author(s)



Jihane Aouni, Jean Noel Bacro, Gwladys Toulemonde, Pierre Colin, Loic Darchy. Utility-based dose selection for phase II dose-finding studies. Therapeutic Innovation & Regulatory Science, Springer, 2021, 55, ⟨10.1007/s43441-021-00273-0⟩. ⟨hal-02491551⟩



Record views


Files downloads